Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL48285 | 0.98 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL20617836 | 0.84 | SLC6A1 (0.33) | CYP19A1 | |
| SCHEMBL27598186 | 0.84 | SLC6A1 (0.33) | CYP19A1 | |
| SCHEMBL27653752 | 0.84 | SLC6A1 (0.33) | CYP19A1 | |
| SCHEMBL27504346 | 0.81 | SLC6A1 (0.40) | CHRNB2CHRNA4ATMCYP19A1 | |
| SCHEMBL27744409 | 0.81 | SLC6A1 (0.40) | CHRNB2CHRNA4ATMCYP19A1 | |
| SCHEMBL27657052 | 0.81 | SLC6A1 (0.40) | CHRNB2CHRNA4ATMCYP19A1 | |
| SCHEMBL27908028 | 0.79 | CYP19A1 (0.38) | ATMCYP19A1 | |
| SCHEMBL914574 | 0.78 | CHRM3 (0.39) | CYP19A1 | |
| SCHEMBL17886845 | 0.78 | CYP19A1 (0.41) | ATMCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626888-A1 | COMPOUNDS | Redx Pharma Limited (GB) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024115890-A1 | COMPOUNDS | REDX PHARMA PLC (GB) | 2024-06-06 | — | — | WO | disclosed |
| CN-110461326-A | Novel substituted N' -hydroxycarbamimidoyl-1, 2, 5-oxadiazole compounds as indoleamine 2, 3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME | 2019-11-15 | — | — | CN | disclosed |
| CN-106061963-B | Heterocyclic modulators of lipid synthesis and combinations thereof | 3-V生物科学股份有限公司 | 2019-10-22 | — | — | CN | disclosed |
| CN-110167934-A | Monocycle and spiro-compound containing cyclobutane and containing azetidine as α V integrin inhibitor | 百时美施贵宝公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-110041250-A | The benzene compound being substituted | EPIZYME股份有限公司 | 2019-07-23 | — | — | CN | disclosed |
| CN-109963834-A | It can be used as the novel azetidine derivatives of cortex catecholaminergic modulators of neurotransmission | 综合研究实验室瑞典股份公司 | 2019-07-02 | — | — | CN | disclosed |
| CN-109843888-A | 6, 7, 8, 9-tetrahydro-3H-pyrazolo [4, 3-f ] isoquinoline derivatives useful for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2019-06-04 | — | — | CN | disclosed |
| CN-109776523-A | Heterocyclic compound and application thereof in medicine | 杭州安霖药业有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109328187-A | A kind of new compound and its preparation and application with FGFR inhibitory activity | 中国科学院上海药物研究所 | 2019-02-12 | — | — | CN | disclosed |
| CN-101903380-A | Amino cyclohexyl methyl-oxazoles of 5-pyridine-2-ketone derivatives | ACTELION PHARMACEUTICALS LTD | 2010-12-01 | — | — | CN | disclosed |
| CN-101678020-A | Quinoxaline derivatives as inhibitors of the tyrosine kinase activity of Janus kinases | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| CN-101679351-A | Quinoline compounds suitable for treating didorders that respond to modulation of the serotonin 5-ht6 receptor | ABBOTT GMBH & CO KG | 2010-03-24 | — | — | CN | disclosed |
| CN-101506140-A | Cyclic 11 beta-hydroxysteroid dehydrogenase type I inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-08-12 | — | — | CN | disclosed |
| CN-101479255-A | c-MET protein kinase inhibitors for the treatment of proliferative disorders | VERTEX PHARMA (US) | 2009-07-08 | — | — | CN | disclosed |
| CN-101454328-A | Novel mch receptor antagonists | LILLY CO ELI (US) | 2009-06-10 | — | — | CN | disclosed |
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-7468443-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| CN-101137628-A | Non-anilinic derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators | ASTRAZENECA AB (SE) | 2008-03-05 | — | — | CN | disclosed |
| CN-101018773-A | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | AHNAK, NGF, PMP22 | CHRNB2 232/4885CHRNA4 251/4885CHRNB4 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.